These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26141817)

  • 1. Off-label indications for mifepristone in gynecology and obstetrics.
    Dzuba IG; Grossman D; Schreiber CA
    Contraception; 2015 Sep; 92(3):203-5. PubMed ID: 26141817
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the introduction of a new treatment for the termination of pregnancy in The Netherlands.
    Brouns JF; Burger MP; van Wijngaarden WJ
    Acta Obstet Gynecol Scand; 2010 Sep; 89(9):1210-3. PubMed ID: 20804347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medical termination of pregnancy by mifepristone and misoprostol - evaluation of succes rate, complications and satisfaction of patients].
    Frank K; Gerychová R; Janků P; Huser M; Ventruba P
    Ceska Gynekol; 2015 Dec; 80(6):451-5. PubMed ID: 26741161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Update on Uses for Mifepristone in Obstetrics and Gynecology.
    Hagey JM; Givens M; Bryant AG
    Obstet Gynecol Surv; 2022 Oct; 77(10):611-623. PubMed ID: 36242531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Status and expertise of off-label use of misoprostol in obstetrics and gynecology in France: study by CNGOF (short text)].
    Marret H; Simon E; Beucher G; Dreyfus M; Gaudineau A; Vayssière C; Lesavre M; Pluchon M; Winer N; Fernandez H; Aubert J; Bejan-Angoulvant T; Jonville-Bera AP; Clouqueur E; Houfflin-Debarge V; Garrigue A; Pierre F;
    J Gynecol Obstet Biol Reprod (Paris); 2014 Feb; 43(2):107-13. PubMed ID: 24438770
    [No Abstract]   [Full Text] [Related]  

  • 6. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
    Gold M; Chong E
    Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical management of unwanted pregnancy in France: modalities and outcomes. The aMaYa study.
    Nisand I; Bettahar K;
    Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():13-8. PubMed ID: 25462213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical methods for first-trimester abortion.
    Nothnagle M; Taylor JS
    Am Fam Physician; 2004 Jul; 70(1):81-3. PubMed ID: 15259521
    [No Abstract]   [Full Text] [Related]  

  • 9. [Off-label use of misoprostol in obstetrics and gynecology: methods and organization].
    Simon EG; Fritel X
    J Gynecol Obstet Biol Reprod (Paris); 2014 Feb; 43(2):103-6. PubMed ID: 24440127
    [No Abstract]   [Full Text] [Related]  

  • 10. Methotrexate and misoprostol to terminate early pregnancy.
    Grunberg SM
    N Engl J Med; 1996 Feb; 334(6):399-400. PubMed ID: 8538717
    [No Abstract]   [Full Text] [Related]  

  • 11. Obstetrician-gynecologists' knowledge of and attitudes toward medical abortion in Guatemala.
    Kestler E
    Int J Gynaecol Obstet; 2012 Feb; 116(2):120-3. PubMed ID: 22093500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Off-label use of misoprostol in obstetrics and gynecology: Introduction].
    Simon EG; Marret H
    J Gynecol Obstet Biol Reprod (Paris); 2014 Feb; 43(2):87-102. PubMed ID: 24440000
    [No Abstract]   [Full Text] [Related]  

  • 13. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial.
    Schreiber CA; Creinin MD; Reeves MF; Harwood BJ
    Contraception; 2006 Dec; 74(6):458-62. PubMed ID: 17157102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Termination of pregnancy in the 2nd trimester: mifepriston/misoprostol preferable to sulprostone].
    Ebbers S; Creemers JW; Lotgering FK
    Ned Tijdschr Geneeskd; 2009; 153():A138. PubMed ID: 19930731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing.
    Fiala C; Safar P; Bygdeman M; Gemzell-Danielsson K
    Eur J Obstet Gynecol Reprod Biol; 2003 Aug; 109(2):190-5. PubMed ID: 12860340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Off-label is Illegal: Implications of Mandating the FDA-approved Protocol for Mifepristone-induced Abortions.
    Britton L; Bryant A
    Womens Health Issues; 2015; 25(5):433-5. PubMed ID: 26169217
    [No Abstract]   [Full Text] [Related]  

  • 17. Medication abortion in the private sector in South Africa.
    Blanchard K; Schaffer K; McLeod S; Winikoff B
    Eur J Contracept Reprod Health Care; 2006 Dec; 11(4):285-90. PubMed ID: 17484194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of misoprostol in pregnancy.
    Hale RW; Zinberg S
    N Engl J Med; 2001 Jan; 344(1):59-60. PubMed ID: 11136964
    [No Abstract]   [Full Text] [Related]  

  • 19. ["Off label" use of some medicinal products. Part II. "Off label" use of misoprostol].
    Sirakov M
    Akush Ginekol (Sofiia); 2012; 51(3):50-4. PubMed ID: 23236666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens français.
    Marret H; Simon E; Beucher G; Dreyfus M; Gaudineau A; Vayssière C; Lesavre M; Pluchon M; Winer N; Fernandez H; Aubert J; Bejan-Angoulvant T; Jonville-Bera AP; Clouqueur E; Houfflin-Debarge V; Garrigue A; Pierre F;
    Eur J Obstet Gynecol Reprod Biol; 2015 Apr; 187():80-4. PubMed ID: 25701235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.